Malaria – A Pipeline Analysis Report 2020-2024 |Technavio

Technavio has announced the latest market research report titled Malaria - A Pipeline Analysis Report 2020-2024 (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on malaria. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat malaria.

Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future. Download Free Sample Report

Malaria : An Overview of the Disease

Malaria is caused by Plasmodium parasites that are transmitted through the bite of female Anopheles mosquitoes. Primary symptoms of the disease include fever, headache, and chills that generally appear within 10-15 days of the infection. As the initial symptoms are mild, it can be difficult to diagnose the disease. While five parasite species have been identified for causing malaria in humans, P. falciparum has a high fatality rate and can lead to death within 24 hours.

According to a senior market research analyst at Technavio, “The incidence of malaria has increased significantly in least developed countries. Cases of malaria are especially high in the African countries. Thus, there is an urgent need to reduce morbidity and mortality, and increase the number of malaria-free countries, which in turn, offers immense opportunities to companies and research institutions.”

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Malaria: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed (monotherapy, and combination therapy), RoA (oral, intravenous, intramuscular, and unknown), therapeutic modalities (small molecules, vaccine, and unknown), drugs under development (discovery, pre-clinical, phase I, phase I/II, and phase II), targets for drug development (P-type ATPase, dihydroorotate dehydrogenase, immune system, Bc1 complex, CSP, TLR5 receptor, PeEF2, and unknown), MoA, and recruitment status (completed, recruiting, active not recruiting, not yet recruiting, and NA). In the current drug pipeline, the most preferred therapeutic modality is small molecule, with more than 64% of the pipeline molecules administered through this mode.

To learn more about the global trends impacting the future of market research, download a free sample: Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • Route of administration (RoA)
  • Therapeutic modalities
  • Targets of Drug Development
  • Mechanism of Action (MoA)
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company overview

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

This malaria diagnostics market report also covers information about the therapeutic assessment of the pipeline molecules.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200